Andere talen Ocumension Therapeutics

Aandelen

1477

KYG674111011

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:42 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,85 ^HKD	+1,63%		+0,15%	+2,54%

15/04	Ocumension Therapeutics kondigt fase III klinische studie van OT-502 in China aan	CI
08/04	Ocumension Therapeutics' oogmedicijn voltooit klinische tests en zal binnenkort een NDA aanvragen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug	15/04
Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China	15/04
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon	08/04
Ocumension Therapeutics Announces Completion of the Phase III Clinical Trial of OT-702 in China	08/04
Ocumension Therapeutics’ Loss for 2023 Narrows; Shares Down 4%	22/03
OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth	21/03
Ocumension Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Ocumension Therapeutics' Phase 2 Trial for Dry Eye Treatment Meets Clinical Endpoints	14/03
Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202	14/03
Ocumension Therapeutics Cuts Shareholding in Nasdaq-Listed EyePoint Pharmaceuticals	17/01
Ocumension Therapeutics Gets Nod to Register Iluvien in Hong Kong	20/12
Ocumension Therapeutics Receives Approval for Marketing OT-703 in Hong Kong	20/12
Ocumension Therapeutics commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.	13/12
Ocumension Says Core Product Added to China's National Reimbursement Drug List	13/12
China Includes Ocumension's Middle Eye Infection Treatment in Drug Reimbursement List	13/12
Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing	08/12
Ocumension Therapeutics Completes Patient Enrollment for Post-Operative Inflammation Drug in China	30/11
Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China	29/11
Ocumension Therapeutics Plans HK$100 Million Share Buyback	29/11
Ocumension Enrolls 213 Patients for Phase II Trial of Eye Medication in China	22/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ocumension Therapeutics

Aandelen

1477

KYG674111011

Andere talen

Filters